Why MapLight Therapeutics, Inc.’s (MPLT) Stock Is Up 8.19%
As of Friday, August 21, MapLight Therapeutics, Inc.’s MPLT share price has surged by 8.19%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Commentary & Analysis
Why MapLight Therapeutics, Inc.’s (MPLT) Stock Is Down 5.50%
As of Friday, August 07, MapLight Therapeutics, Inc.’s MPLT share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MapLight Therapeutics, Inc.’s (MPLT) Stock Is Up 5.23%
As of Friday, July 31, MapLight Therapeutics, Inc.’s MPLT share price has surged by 5.23%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why MapLight Therapeutics, Inc.’s (MPLT) Stock Is Down 6.13%
As of Thursday, July 30, MapLight Therapeutics, Inc.’s MPLT share price has dipped by 6.13%, which has investors questioning if this is right time to buy.Michael Rose
Why MapLight Therapeutics, Inc.’s (MPLT) Stock Is Up 10.97%
As of Wednesday, July 29, MapLight Therapeutics, Inc.’s MPLT share price has surged by 10.97%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MPLT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $519.9 | $292.6 | 37% |
|
| Shares Out (Mil) | 45.4 | 54.4 | 45% |
|
| Institutional Ownership | 91.4% | 93.2% | 59% |
|
| Float (Mil) | 16.7 | 40.2 | 26% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 540 | 544 | 59% |
|
| Price Change (52-week) |
na | 59.7% | na |
|
| Growth | MPLT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 9 | |
| Current EPS | ($1.088) | ($4.596) | ($3.335) | |
| Month Ago EPS | ($1.251) | ($5.081) | ($3.798) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($1.216) | ($4.932) | ($4.478) | |
| Year/Year Chg | (17.9%) | (75.2%) | (81.3%) | |
| Financials | MPLT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($230) | ($43) | 6% |
|
| EPS (TTM) | ($7.419) | ($1.400) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($175) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $38 | $2 | 67% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | $242 | $164 | 28% |
|
| Valuation | MPLT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.46 | 2.83 | 37% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MPLT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (101.6%) | (47.5%) | 5% |
|
| ROE | (445.2%) | (55.0%) | 1% |
|
| Liabilities to Assets | 5.4% | 29.6% | 3% |
|
| F-Score | 2 | 3 | 7% |
|
MapLight Therapeutics, Inc. did not pass any screens on 8/21/2026.
